MCID: INT080
MIFTS: 45

Intraocular Melanoma

Categories: Genetic diseases, Rare diseases, Skin diseases

Aliases & Classifications for Intraocular Melanoma

MalaCards integrated aliases for Intraocular Melanoma:

Name: Intraocular Melanoma 53 29 6
Uveal Melanoma 53 73
Melanoma of the Uvea 53

Classifications:



External Ids:

UMLS 73 C0220633

Summaries for Intraocular Melanoma

NIH Rare Diseases : 53 Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract.  The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases (90%) of intraocular melanoma develop in the choroid, called choroidal melanoma; the ciliary body is less commonly a site of origin, and the iris is the least common.  Each manifests with different clinical features and symptoms. Treatment depends on the site of origin (choroid, ciliary body, or iris), size and location of the tumor, the age of the individual, and other factors. 

MalaCards based summary : Intraocular Melanoma, also known as uveal melanoma, is related to melanoma, uveal and melanoma, cutaneous malignant 1. An important gene associated with Intraocular Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are Pathways in cancer and Aldosterone synthesis and secretion. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and t cells, and related phenotype is pigmentation.

Related Diseases for Intraocular Melanoma

Diseases in the Intraocular Melanoma family:

Melanoma, Malignant Familial Intraocular

Diseases related to Intraocular Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Related Disease Score Top Affiliating Genes
1 melanoma, uveal 33.3 GNA11 GNAQ
2 melanoma, cutaneous malignant 1 29.4 GNA11 GNAQ
3 posterior uveal melanoma 12.5
4 necrotic uveal melanoma 12.4
5 mixed cell uveal melanoma 12.3
6 spindle cell intraocular melanoma 12.3
7 tumor predisposition syndrome 11.4
8 bap1 tumor predisposition syndrome 11.2
9 uveal epithelioid cell melanoma 11.2
10 choroid spindle cell melanoma 11.2
11 ciliary body spindle cell melanoma 11.2
12 iris spindle cell melanoma 11.2
13 ocular melanoma 11.2
14 melanoma 10.7
15 retinoblastoma 10.4
16 neovascular glaucoma 10.3
17 myotonic dystrophy 10.3
18 myotonia atrophica 10.3
19 macular retinal edema 10.2
20 anxiety 10.1
21 herpes simplex 10.1
22 depression 10.1
23 dysplastic nevus syndrome 10.1
24 skin melanoma 10.1
25 insulin-like growth factor i 10.1
26 cataract 10.1
27 uveitis 10.1
28 optic nerve disease 10.1
29 neuropathy 10.1
30 hypoxia 10.1
31 large cell carcinoma 10.0
32 lymphoma, mucosa-associated lymphoid type 9.9
33 macular dystrophy, dominant cystoid 9.9
34 exfoliation syndrome 9.9
35 halo nevi 9.9
36 pancreatic cancer 9.9
37 coats disease 9.9
38 light fixation seizure syndrome 9.9
39 lung cancer susceptibility 3 9.9
40 burns 9.9
41 multinodular goiter 9.9
42 inflammatory bowel disease 9.9
43 lymphoma 9.9
44 microphthalmia 9.9
45 primary hyperparathyroidism 9.9
46 goiter 9.9
47 scleritis 9.9
48 hyperparathyroidism 9.9
49 optic disk drusen 9.9
50 panophthalmitis 9.9

Graphical network of the top 20 diseases related to Intraocular Melanoma:



Diseases related to Intraocular Melanoma

Symptoms & Phenotypes for Intraocular Melanoma

MGI Mouse Phenotypes related to Intraocular Melanoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 8.62 GNA11 GNAQ

Drugs & Therapeutics for Intraocular Melanoma

Drugs for Intraocular Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
8 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
10 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
12 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
13 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
14 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
15
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
16
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
17
Fotemustine Experimental, Investigational Phase 3
18 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
19 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
22
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
23
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
24
Nicotinamide Approved, Investigational Phase 2,Phase 1 98-92-0 936
25
Sunitinib Approved, Investigational Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102
26
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Tamoxifen Approved Phase 2 10540-29-1 2733526
29
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
30
Pasireotide Approved Phase 2 396091-73-9 9941444
31
Everolimus Approved Phase 2 159351-69-6 6442177
32
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
33
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
34
Somatostatin Approved, Investigational Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
35
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
36
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
37
Ethiodized oil Approved, Investigational Phase 2 8008-53-5
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
39
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
40
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
41
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
42
Aluminum sulfate Approved Phase 2 10043-01-3
43
Aldesleukin Approved Phase 1, Phase 2,Phase 2 85898-30-2, 110942-02-4
44
Leuprolide Approved, Investigational Phase 2 53714-56-0 657181 3911
45
Vorinostat Approved, Investigational Phase 2,Early Phase 1 149647-78-9 5311
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
Pancrelipase Approved, Investigational Phase 2 53608-75-6
48
Fludarabine Approved Phase 2,Phase 1 75607-67-9, 21679-14-1 30751
49
Iodine Approved, Investigational Phase 2,Phase 1 7553-56-2 807
50
Nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 145)
# Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
3 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
5 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
6 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
7 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
8 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
9 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
10 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
11 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Unknown status NCT02936388 Phase 2
12 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
13 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma Unknown status NCT01551459 Phase 2 Dacarbazine;Sunitinib
14 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
15 Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) Unknown status NCT02874040 Phase 2
16 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
17 Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Unknown status NCT02586727 Phase 2 aflibercept
18 Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma Completed NCT01979523 Phase 2 Trametinib;Uprosertib
19 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
20 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
21 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
22 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
23 Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed NCT02363283 Phase 2 Glembatumumab Vedotin
24 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
25 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2 GM-CSF
26 Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003339 Phase 2
27 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
28 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
29 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
30 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
31 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
32 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
33 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
34 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
35 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
36 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
37 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
38 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
39 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
40 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
41 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
42 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
43 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
44 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
45 Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Completed NCT01835145 Phase 2 Cabozantinib S-malate;Dacarbazine;Temozolomide
46 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
47 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00450255 Phase 2
48 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed NCT00121225 Phase 2 vorinostat
49 Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma Completed NCT01961115 Phase 2 Epacadostat
50 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib

Search NIH Clinical Center for Intraocular Melanoma

Genetic Tests for Intraocular Melanoma

Genetic tests related to Intraocular Melanoma:

# Genetic test Affiliating Genes
1 Intraocular Melanoma 29

Anatomical Context for Intraocular Melanoma

MalaCards organs/tissues related to Intraocular Melanoma:

41
Liver, Eye, T Cells, Bone, Testes, Bone Marrow, Skin

Publications for Intraocular Melanoma

Articles related to Intraocular Melanoma:

(show top 50) (show all 715)
# Title Authors Year
1
Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review. ( 30455614 )
2019
2
MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy. ( 28818442 )
2018
3
Visualization and Quantitative 3D Analysis of Intraocular Melanoma and Its Vascularization in a Hamster Eye. ( 29364141 )
2018
4
Herpes simplex virus type 1 infection promotes the growth of a subpopulation of tumor cells in 3D uveal melanoma cultures. ( 30045986 )
2018
5
An 11-gene-based prognostic signature for uveal melanoma metastasis based on gene expression and DNA methylation profile. ( 30556166 )
2018
6
Selective PKCδ inhibitor B106 elicits uveal melanoma growth inhibitory effects independent of activated PKC isoforms. ( 30525429 )
2018
7
Response to "Selective PKCδ inhibitor B106 elicits uveal melanoma growth inhibitory effects independent of activated PKC isoforms". ( 30525445 )
2018
8
Posterior uveal melanoma in adolescents and children: current perspectives. ( 30464381 )
2018
9
Reflections on a Health Psychology Service for Patients with Uveal Melanoma: The Challenge of Psychological Screening and Intervention When Distress is 'Normal'. ( 30465122 )
2018
10
Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma. ( 30477459 )
2018
11
Molecular and immunohistochemical analyses of uveal melanoma patient cohort. ( 30480620 )
2018
12
TRPM8 Activation via 3-Iodothyronamine Blunts VEGF-Induced Transactivation of TRPV1 in Human Uveal Melanoma Cells. ( 30483120 )
2018
13
CORRELATION OF GENE EXPRESSION PROFILE STATUS AND AMERICAN JOINT COMMISSION ON CANCER STAGE IN UVEAL MELANOMA. ( 30418387 )
2018
14
Clinical Features, Metastasis, and Survival in Patients Younger Than 21 Years With Posterior Uveal Melanoma. ( 30422230 )
2018
15
Nevus of Ota associated with a primary uveal melanoma and intracranial melanoma metastasis. ( 30372724 )
2018
16
Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma. ( 30381389 )
2018
17
Modifications of Callender's Classification of Uveal Melanoma at the Armed Forces Institute of Pathology. ( 30384958 )
2018
18
Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma. ( 30400891 )
2018
19
Effects of ranibizumab and amfenac on the functional abilities and radiosensitivity of uveal melanoma cells. ( 30403264 )
2018
20
The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability. ( 30320917 )
2018
21
Uveal melanoma survival rates after single dose stereotactic radiosurgery. ( 30334446 )
2018
22
Role of epigenetic deregulation in hematogenous dissemination of malignant uveal melanoma. ( 30334454 )
2018
23
Knockdown of thrombospondin 2 inhibits metastasis through modulation of PI3K signaling pathway in uveal melanoma cell line M23. ( 30338785 )
2018
24
Transcription of the Human 5-Hydroxytryptamine Receptor 2B (HTR2B) Gene Is under the Regulatory Influence of the Transcription Factors NFI and RUNX1 in Human Uveal Melanoma. ( 30347896 )
2018
25
Prognostication of metastatic death in uveal melanoma patients: A Markov multi-state model. ( 30278339 )
2018
26
Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients. ( 30284368 )
2018
27
Complete response to pembrolizumab after initial progress in a patient with metastatic uveal melanoma. ( 30299577 )
2018
28
Extrascleral Tumor Extension Associated with Localized Scleral Melt following Plaque Brachytherapy for Uveal Melanoma: Clinical and Histologic Findings. ( 30320088 )
2018
29
Response to "Comparison of Gene Expression Profiling and Chromosome 3 Analysis by Fluorescent in situ Hybridization and Multiplex Ligation Probe Amplification in Fine-Needle Aspiration Biopsy Specimens of Uveal Melanoma". ( 30320094 )
2018
30
Conjunctival Dehiscence and Scleral Necrosis following Iodine-125 Plaque Brachytherapy for Uveal Melanoma: A Report of 3 Cases. ( 30320099 )
2018
31
BAP1 Immunostaining in Uveal Melanoma: Potentials and Pitfalls. ( 30320100 )
2018
32
Chromosome 3 is a valid marker for prognostic testing of biopsy material from uveal melanoma later treated by brachytherapy. ( 30265160 )
2018
33
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. ( 30205280 )
2018
34
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. ( 30211813 )
2018
35
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. ( 30234393 )
2018
36
Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. ( 30174161 )
2018
37
Clarification on Uveal Melanoma Associated With Myotonic Dystrophy. ( 30193301 )
2018
38
Clarification on Uveal Melanoma Associated With Myotonic Dystrophy. ( 30193333 )
2018
39
Clarification on Uveal Melanoma Associated With Myotonic Dystrophy-Reply. ( 30193376 )
2018
40
Uveal Melanoma Associated With Myotonic Dystrophy: A Report of 6 Cases. ( 29596556 )
2018
41
Recent advancements in the management of retinoblastoma and uveal melanoma. ( 29755733 )
2018
42
Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma. ( 30093564 )
2018
43
Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma. ( 30094568 )
2018
44
Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes. ( 30107825 )
2018
45
Staging Uveal Melanoma with Whole-Body Positron-Emission Tomography/Computed Tomography and Abdominal Ultrasound: Low Incidence of Metastatic Disease, High Incidence of Second Primary Cancers. ( 30122854 )
2018
46
Intraocular biopsy of uveal melanoma Risk assessment and identification of genetic prognostic markers. ( 30133961 )
2018
47
Role of microRNA-21 in uveal melanoma cell invasion and metastasis by regulating p53 and its downstream protein. ( 30140627 )
2018
48
Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma. ( 29185101 )
2018
49
Novel therapeutic strategies and targets in advanced uveal melanoma. ( 29206651 )
2018
50
Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma. ( 29233905 )
2018

Variations for Intraocular Melanoma

ClinVar genetic disease variations for Intraocular Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
2 GNAQ NM_002072.4(GNAQ): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
3 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh37 Chromosome 9, 80409488: 80409488
4 GNAQ NM_002072.4(GNAQ): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913492 GRCh38 Chromosome 9, 77794572: 77794572
5 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
6 GNA11 NM_002067.4(GNA11): c.626A> C (p.Gln209Pro) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
7 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh37 Chromosome 19, 3118942: 3118942
8 GNA11 NM_002067.4(GNA11): c.626A> T (p.Gln209Leu) single nucleotide variant Pathogenic/Likely pathogenic rs1057519742 GRCh38 Chromosome 19, 3118944: 3118944
9 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh37 Chromosome 9, 80409488: 80409489
10 GNAQ NM_002072.4(GNAQ): c.625_626delCAinsTT (p.Gln209Leu) indel Likely pathogenic rs1057519853 GRCh38 Chromosome 9, 77794572: 77794573

Expression for Intraocular Melanoma

Search GEO for disease gene expression data for Intraocular Melanoma.

Pathways for Intraocular Melanoma

Pathways related to Intraocular Melanoma according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1 12.38 GNA11 GNAQ
2
Show member pathways
12.32 GNA11 GNAQ
3
Show member pathways
12.29 GNA11 GNAQ
4
Show member pathways
12.23 GNA11 GNAQ
5
Show member pathways
12.17 GNA11 GNAQ
6 12.17 GNA11 GNAQ
7
Show member pathways
12.12 GNA11 GNAQ
8
Show member pathways
12.02 GNA11 GNAQ
9
Show member pathways
11.97 GNA11 GNAQ
10
Show member pathways
11.93 GNA11 GNAQ
12
Show member pathways
11.86 GNA11 GNAQ
13
Show member pathways
11.79 GNA11 GNAQ
14
Show member pathways
11.76 GNA11 GNAQ
15
Show member pathways
11.67 GNA11 GNAQ
16 11.66 GNA11 GNAQ
17
Show member pathways
11.64 GNA11 GNAQ
18
Show member pathways
11.62 GNA11 GNAQ
19
Show member pathways
11.58 GNA11 GNAQ
20 11.54 GNA11 GNAQ
21 11.48 GNA11 GNAQ
22 11.45 GNA11 GNAQ
23 11.38 GNA11 GNAQ
24 11.31 GNA11 GNAQ
25 11.22 GNA11 GNAQ
26 11.19 GNA11 GNAQ
27 11.15 GNA11 GNAQ
28 11.03 GNA11 GNAQ
29 10.87 GNA11 GNAQ
30 10.85 GNA11 GNAQ
31 10.7 GNA11 GNAQ
32 10.49 GNA11 GNAQ
33
Show member pathways
9.83 GNA11 GNAQ

GO Terms for Intraocular Melanoma

Cellular components related to Intraocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosomal membrane GO:0005765 9.16 GNA11 GNAQ
2 photoreceptor outer segment GO:0001750 8.96 GNA11 GNAQ
3 heterotrimeric G-protein complex GO:0005834 8.62 GNA11 GNAQ

Biological processes related to Intraocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet activation GO:0030168 9.37 GNA11 GNAQ
2 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.32 GNA11 GNAQ
3 action potential GO:0001508 9.26 GNA11 GNAQ
4 G protein-coupled acetylcholine receptor signaling pathway GO:0007213 9.16 GNA11 GNAQ
5 phototransduction, visible light GO:0007603 8.96 GNA11 GNAQ
6 entrainment of circadian clock GO:0009649 8.62 GNA11 GNAQ

Molecular functions related to Intraocular Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GTP binding GO:0005525 9.37 GNA11 GNAQ
2 GTPase activity GO:0003924 9.32 GNA11 GNAQ
3 G protein-coupled receptor binding GO:0001664 9.26 GNA11 GNAQ
4 G-protein beta/gamma-subunit complex binding GO:0031683 9.16 GNA11 GNAQ
5 guanyl nucleotide binding GO:0019001 8.96 GNA11 GNAQ
6 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Intraocular Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....